DUBLIN, June 9, 2022 /PRNewswire/ -- The "Human Microbiome Market: Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy: Distribution by Type of Molecule, Type of Product, Target Indication, Therapeutic Areas, Supply Channels and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to
ResearchAndMarkets.com's offering.
The 'The Human Microbiome Market (4th Edition), 2022-2035' report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of microbiome-based therapeutics, diagnostics and FMTs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.
One of the key objectives of the report was to estimate the existing market size and future growth opportunity for microbiome therapeutics, diagnostics and FMTs, over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends of the sales, of approved / late stage (estimated) microbiome therapeutics, diagnostic products and FMTs.
In order to account for the uncertainties associated with the growth of microbiome market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
The ongoing research efforts, focused on targeting and modulating microbiome, have led to the development of treatment options for more than 25 indications. In addition, probiotic therapies with live biotherapeutic products (microbes) are considered to be the most advanced microbiome-based therapies for restoring bacterial symbiosis.
At present, fecal microbiota transplantation (FMT) involving the transfer of complete microbial community from a healthy donor's feces to recipient via oral (in form of a capsule) or rectal (enema and colonoscopy) is the only FDA-approved microbiome therapy, for the treatment of recurrent CDI. However, several players are engaged in developing prescription drugs modulating human microbiome for the treatment of various gastrointestinal and non-gastrointestinal disorders as well. Further, a number of microbiome diagnostic and screening / profiling tests are commercially available for the detection of different microbiome-related diseases. It is worth mentioning that, owing to the rising interest, a number of start-ups / small firms have established in the past few years and the contributions of big pharma players have fueled the overall growth in this domain.
Driven by increasing prevalence of disease indications, promising therapeutic potential of microbiome-based therapies, encouraging clinical trial results and financial support from the investors, the human microbiome therapeutics and diagnostics market is likely to witness substantial growth in the mid to long-term.
The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company / organization names):
Lee Jones (President and Chief Executive Officer, Rebiotix) Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic) Nikole Kimes (Co-founder and Chief Executive Officer, Siolta Therapeutics)
James Burges (Co-founder and Vice President of Innovation, Finch Therapeutics)
Debbie Pinkston (Former Vice President, Sales and Business Development, List Biological Laboratories)
Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics)
Mark Heiman (Chief Scientific Officer and Vice President, Research, Scioto Biosciences) Alexander Segal (Founder, Stealth Startup)
Assaf Oron (Chief Business Officer, BiomX) Pierre-Alain Bandinelli (Chief Strategy Officer, Da Volterra)
Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories)
Charlie Badham (Senior Manager, Corporate Development, 4D Pharma) Who are the leading players engaged in the development of microbiome therapeutics?
Which are the key drugs being developed across various stages of development?
Which companies are actively involved in conducting clinical trials for microbiome therapeutics and FMTs?
Who are the leading players engaged in the development of microbiome diagnostics and screening / profiling tests?
What kind of partnership models are commonly adopted by industry stakeholders?
Who are the key investors active in the field of human microbiome therapeutics and diagnostics?
What are the different initiatives undertaken by big pharma players for the development of human microbiome therapeutics in the recent past?
What is the role of various start-ups engaged in the developing human microbiome therapeutics?
Which are the most commonly targeted therapeutic indications for microbiome therapeutics are being developed?
What are the various steps involved in the manufacturing of microbiome therapeutics and what are the key considerations for selecting a CMO / CRO?
What are the various algorithms / tools used to analyze data generated from microbiome research?
How is the current and future opportunity, related to microbiome therapeutics, diagnostics and FMT likely to be distributed across key market segments? What are the various non-pharma applications of microbiome products?
1.3. Key Questions Answered
3.3. Overview of Gut Flora
3.4. The Microbiome and Associated Diseases
3.6. Impact of Microbiota on Therapeutic Outcomes 3.8. The Human Microbiome Project (HMP)
3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)
4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE
4.2. Microbiome Therapeutics: Clinical Pipeline
4.3. Microbiome Therapeutics: Preclinical Pipeline
4.4. Microbiome Therapeutics: List of Drug Developers
5. MICROBIOME THERAPEUTICS: COMPANY AND DRUG PROFILES
5.2. Microbiome Therapeutics Developers: Companies with Candidate(s) in Highest Phase of Development
5.9. Microbiome Therapeutics Developers: Companies with Maximum Number of Therapeutic Programs
6. CLINICAL TRIAL ANALYSIS: HUMAN MICROBIOME THERAPEUTICS 6.2. Human Microbiome Therapeutics: List of Clinical Trials
7.2. Overview of Microbiome Diagnostics and Screening / Profiling Tests
7.3. Microbiome Diagnostics and Screening / Profiling Tests: Marketed and Under Development Products 7.4. Microbiome Diagnostic and Screening / Profiling Tests Providers
8. MICROBIOME DIAGNOSTIC AND SCREENING / PROFILING TEST PROVIDERS: COMPANY PROFILES
9. FECAL MICROBIOTA THERAPY (FMT)
9.2. Introduction to Fecal Microbiota Therapy
9.4. Fecal Microbiota Therapy: Procedure and Clinical Relevance
9.5. Regulatory Guidelines Related to Fecal Microbiota Therapy
9.6. Insurance Coverage for Fecal Microbota Therapy
9.7. Fecal Microbiota Therapy: Marketed and Development Pipeline
9.8. Fecal Microbiota Therapy: List of Developers
10. CLINICAL TRIALS ANALYSIS: FECAL MICROBIOTA THERAPY
11. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX
11.2. AC Matrix: An Overview
11.3. AC Matrix: Analytical Methodology
11.4. AC Matrix: Plotting the Information
11.5. AC Matrix: Analyzing the Data
12. MICROBIOME RELATED INITIATIVES OF BIG PHARMA PLAYERS
12.2. Scope and Methodology
12.3. Initiatives of Big Pharma Players
12.4. Benchmarking Analysis of Big Pharma Players
13.2. Scope and Methodology
13.3. Benchmarking of Start-ups
14. KEY THERAPEUTIC AREAS
14.4. Oncological Indications
15. PARTNERSHIPS AND COLLABORATIONS
15.3. Human Microbiome: List of Partnerships and Collaborations
15.4. Analysis by Year of Partnership
15.5. Analysis by Type of Partnership
15.6. Analysis by Year and Type of Partnership
15.7. Analysis by Type of Product
15.8. Analysis by Target Indication
15.9. Analysis by Therapeutic Area
15.10. Analysis by Type of Company
15.11. Analysis by Type of Partner
15.12. Most Active Players: Analysis by Number of Partnerships 16.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments 17. CASE STUDY: CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS AND LIVE BIOTHERAPEUTICS 17.3. Key Considerations for Selecting a CMO / CRO Partner
18. BIG DATA AND MICROBIOME THERAPEUTICS
18.3. Internet of Things (IoT)
18.4. Growing Interest in Big Data: Google Trends Analysis
18.5. Key Application Areas
18.6. Big Data in Microbiome Research
18.7. Big Data Services for Microbiome Research: List of Companies
18.8. Big Data Services for Microbiome Research: Profiles of Key Players
19. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS 19.4. Global Microbiome Therapeutics Market, 2022-2035 19.5. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2022-2035
20.3 Forecast Methodology
20.4. Global Microbiome Diagnostics Market, 2022-2035 20.5. Microbiome Diagnostics Market: Distribution by Target Indication, 2022-2035
20.6. Microbiome Diagnostics Market: Distribution by Therapeutic Area, 2022-2035
20.7. Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035
20.8. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035
21. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS 21.5. Overall Microbiome Market by Product Offerings, 2022-2035
22.3. Applications of Microbiome Based Products in Agriculture Industry
22.4. Future Perspectives
24.4. Pendulum Therpaeutics
25. APPENDIX I: TABULATED DATA
26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/fsj5me
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716